Clinical trial
Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV…
NCT00429481 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00429481 |
|---|---|
| Title | Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine at Different Viral Concentrations in Healthy Infants |
| Official title | Study to Assess Efficacy, Immunogenicity, Reactogenicity and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus Vaccine at Different Viral Concentrations in Healthy Infants Previously Uninfected With Human Rotavirus and Approximately 3 Months of Age. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Biological |
| Interventions | Rotarix |
| Enrollment | 2,464 |
| Start date | Jan 1, 2001 |
| Primary completion | Apr 1, 2003 |
| Completion | Apr 1, 2003 |
| First posted | Jan 31, 2007 |
| Last update posted | Sep 16, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: